RETINA. OCT in the Optometric Prac4ce OCT. New stuff 11/7/17 AMD. Disclosure Statement

Similar documents
OCT Angiography The Next Frontier

How Strongly Do You Feel That This Patient Has Glaucoma? % % % % %

My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

Mark Dunbar: Disclosure

Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control

Retina Grandrounds. Retinal Grand Rounds Exhibition of Common Entities

Diabetic Retinopatathy

My Doc told me I needed an eye exam because.. Bruce Onofrey, OD, RPh, FAAO Professor, U. Houston UEI

Re(nal and OCT Grand Rounds

Re)nal and OCT Grand Rounds. What's new in OCT? Principles of AngioVue OCTA. Vascular Imaging No Referral Needed 3/9/18. Spectral Domain: Many Op3ons

Course # Getting to Know Your OCT

Retinal Plaques. Prevalence RISK FACTORS. Prevalence. Retinal Plaques 1/16/19

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

8/6/17. Disclosures Aerie Pharmaceuticals Alcon BioTissue Diopsys Optovue Shire

Re(nal and OCT Grand Rounds

VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.

Posterior Segment Update

OCT Interpretation in Retinal Disease

Retinal Disease: What the Periphery Holds Jeffry D. Gerson, O.D., F.A.A.O.

1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

Is this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD. Optometry s Meeting 2015 Seattle, WA

Posterior Segment Disease: Case Challenges

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Vascular Disease Ocular Manifestations of Systemic Hypertension

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences

Patient 1. Grand Rounds. Medical History. Ocular History. Medications. Exam 10/28/ year old African American male. Blur OD x 3 months

11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES

Steven Ferrucci, OD. FAAO; Jeffry Gerson, OD, FAAO; Robert Prouty, OD, FAAO; Leo semes OD, FAAO

Retinal Vein Occlusion

Often asymptomatic but can cause a reduction in BCVA and distortion of vision.

Re)nal and OCT Grand Rounds

ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences

Case Follow Up. Sepi Jooniani PGY-1

OCT Interpretation. Financial Disclosure. Jay M. Haynie, OD, FAAO. OCT Image Layers 7/21/2014

Optometric Postoperative Cataract Surgery Management

Early diagnosis and treatment of VMT with single Intravitreal Injection of Pharmacologic Vitreolysis. Stratos Gotzaridis MD Athens

Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic

ABCs. ABCs of retinal disease !"#$"%!& Disclosures. ABCs three major threats to vision where 1 o care intervention may be helpful!a = AMD !

Billing Requirements for Intravitreal Injections. Financial Interest. Indications. Documentation. Documentation. Documentation

FROM OUTDATED TO UPDATED Eminence-Based Medicine

OCCLUSIVE VASCULAR DISORDERS OF THE RETINA

Optical Coherence Tomography (OCT)

Hypertensive Retinopathy. Hypertensive Retinopathy. Hypertensive Retinopathy. Hypertensive Retinopathy. Hypertensive Retinopathy 12/12/16

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

Managing the Vitreomacular Interface

Ophthalmology Macular Pathways

Introduction. Pardon the Objection: Posterior Segment Update. Disclosures. Introduction. Steven Ferrucci, OD, FAAO 5/23/2014. Fast paced! Interactive!

Measures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity.

Disclosures. Definitions. Goals. Imaging and glaucoma 3/22/2016

DISCLOSURE: What to do? 2/22/2016

Practical Care of the Cataract Patient with Retinal Disease

Interesting, unusual and eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre

Interesting, unusual, eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN

My Doctor told me I needed an eye exam because..

Retina Grand Rounds Jeffry D. Gerson, O.D., F.A.A.O. Grand Rounds basically means license to do whatever you want

EPIRETINAL MEMBRANE & VITREOMACULAR TRACTION

Financial Disclosures

Goals/Objectives. Disclosures. Risk Factors RAO and RVO. Risk Factors. Retinal Artery Occlusions Branch and Central

Ophthalmic Imager Role

CSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.

VMA at the macula resulting in VMT

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

When to Refer to RETINA. Joseph M. Coney, MD February 17, 2017 Memphis, TN

Vanderbilt Eye Institute Clinical Trials

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Do You See What I See!!! Shane R. Kannarr, OD

Diabetic Retinopathy A Presentation for the Public

Interactive Grand Rounds

Diabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

My Doctor told me I needed an eye exam because.. Bruce Onofrey, OD, RPh, FAAO Professor, U. Houston UEI

Consulting Fee: Alcon Laboratories

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute

What is diabetes? Ocolusystemic Disease Essen6als. Statistics, cont. Statistics. Statistics. The Diabetes Epidemic 9/5/12

Implementing New & Revised ICD-10 Codes

An A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department

The Human Eye. Cornea Iris. Pupil. Lens. Retina

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

Clinically Significant Macular Edema (CSME)

OCT Angiography in Primary Eye Care

Facts About Diabetic Eye Disease

Revitalization of the Anterior Segment: Corneal Transplantation and Secondary Lens Repair

Disclosures. Objectives 1/28/2019. None. To review a selection of retina journal publications from 2018 that have broad clinical relevance

Charles C. Wykoff MD PhD Rahul N. Khurana MD

A Curious Case of Bilateral Optic Disc Edema Brittney Dautremont, DO, MPH

Common Causes of Vision Loss

Objectives. Unexplained Vision Loss: Where Do I Go From Here. History. History. Drug Induced Vision Loss

Re)nal and OCT Grand Rounds

HOW TO MAKE THE MOST OF A NEW OCT. with Kelly Kerksick, OD

Ocular Manifestations of Systemic Disease: Grand Rounds Kimberly K. Reed, O.D., FAAO

Age-Related. macular degeneration.

CHAPTER 13 CLINICAL CASES INTRODUCTION

Hypertensive Retinopathy. Cloak and Dagger: re2nal clues to systemic disease. Hypertensive Retinopathy. Hypertensive Retinopathy

Vascular anatomy. Retinal Vascular Disorders. Bring it to the basics! Vascular anatomy. Choroid. Clinical Challenges (Dx a/o Tx) 3/15/2016

Optical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP

Transcription:

Disclosure Statement OCT in the Optometric Prac4ce Steven Ferrucci, OD, FAAO Chief, Optometry Sepulveda VA Professor, SCCO/MBKU Speakers bureau/advisory Board Alcon B&L Centervue Genentech MacuLogix Optovue Science Based Health OCT AMD DME ERM/VMT CSR Macula edema from BRVO/CRVO Plaquenil screening Macular Holes Glaucoma New stuff More scans Up to 70K Widefield 12x9 mm vs. standard 6x6 mm OCT angiography Anterior segment Angles Pachymetry Epithelial mapping RETINA AMD 1

Dry AMD Widefield 83 yo male Followed >13 years for dry AMD VA 20/25 OU since 2013 AREDS 2 BID: reports good compliance Notes vision has go]en blurrier Metamorphosia OU x 2 mos Assessment/plan DRY AMD OS>OD Stage 3 OU Mul4ple confluent drusen OU No fluid on OCT Con4nue AREDS 2 BID HAG RTC 3 mos for repeat OCT Wet AMD 81 year old male h/o POAG for years T ½ and Latanaprost h/o dry AMD OU for years Last VA: 20/40 OD, 20/30 OS Rarely does HAG Type 2 DM for years No re4nopathy or CSME Wet AMD OCT-Widefield In for 3 mos follow-up Reports lost glasses VA Today: 20/40 OD 20/70 OS Did not no4ce a change un4l checked in clinic Again, rarely does Amsler 2

11/7/17 OCT-A OS Re4na Clinic Wet AMD OS Avas4n series x 3 OS. Repeat OCT/OCT-A afer 3rd injec4on AMD Change in VA or metamorphopsia should always be taken seriously OCT to rule out fluid FA/ OCT-A if needed Evidence of heme or fluid should be referred ASAP for treatment Earlier treatment/smaller lesion size correlates with be]er final visual acuity DIABETES/DME CHANGE IN VA OR METAMORPHPSIA IN DRY AMD PT IS CONVERSION TO WET UNTIL RULED OUT!!! 3

DM case 1 Widefield 47 y o AA male Type 2 DM x 10 years Glipizide, mejormin Last A1c 9.9 LEE: 5 years ago at Lenscrafers VA 20/20 OU CSME suspected OD temporal to macula Assessment/plan Mild NPDR OU Mild non-central DME OD, no DME OS Pt ed re BS control Pt states adjus4ng meds with PCP as we speak RTC 3-4 mos repeat OCT OD Refer to re4na if increasing edema or decreasing VA 63 year old male Type 2 DM x 10 years Insulin x 3 years Last A1c 9.7 (h) DM case 2 VA 20/30- OD, 20/25+ OS CSME OD noted on clinical exam Widefield Re4na Clinic Center involved DME OD Discuss with re4na clinic An4-Vegf x 3 Repeat OCT afer 3 rd injec4on Pt ed re BS/BP control 4

DM case 3 50 year old male Type 2 DM x 20 years Last A1c 8.7 Insulin and liraglu4de (Victoza) Reduced VA OD x 9 mos h/o injec4ons OD last year Told earlier this year no more injec4ons needed. Unclear why VA decreased OD Schedule FA DM case 3 Moderate NPDR OU No center involved DME OD Macular ischemia OD>>OS on OCTA No need to do FA No treatment available Op4mize acuity Op4mize BP/BS control RTC 3 mos. Repeat OCT/ OCTA DM/DME Refer if center involved DME/CSME evident on OCT in 1-2 weeks If not center involved, follow closely in 3-6 mos OCT if unexplained vision loss in pt with diabetes Look for ischemia Pt ed re role of BS/BP control Treatment: FML vs. serial an4-vegf ERM ERM 68 year old male h/o oc htn on generic latanprost qhs OUx 3 years Pre tx IOPs 30 Post treatment mid teens VF full OU In for IOP check. Doing well, good compliance, but notes mild decrease VA OD with metamorphosia when reading small print 5

En Face ERM #2 83 year old male Catarct sx ou x2015 Notes OS blurrier than OD HTN BCVA 20/20 OD, 20/25 Os ERM Case #3 70 yo Hispanic male Notes decreased VA OD since previous exam Last year 20/20 OU Mild HTN, early cataracts BCVA 20/30 OD 20/20 OS Assessment ERM OD Plan ERM #3 Will monitor due to good VA RTC 6 mos ERM AGE INCIDENCE < 60 1.7% 60-69 7.2% 70-79 11.6% 80+ 9.3% BLUE MOUNTAIN EYE STUDY, AUSTRALIA 6

ERM Consider surgery if: VA 20/40ish or worse Symptomatic Visual need of patient Make sure you have an experienced surgeon!! VMT VMT case 82 year old male In for yearly exam Notes no change in vision h/o mild to moderate cataracts, VA 20/30 OU VA today 20/40 OD- one line decrease 20/30 OS-stable VMT CASE VMT OS with 20/40 acuity Discussion re op4ons Surgery Monitor Pt elects to monitor, as not bothered by vision and would like to avoid surgery RTC 3 mos with repeat OCT. Pt agrees with plan 7

VMT CASE 2 70 year old male in for rou4ne exam Notes mild change in distance vision, both eyes, since last exam 1 yr ago Thinks he needs new glasses 20/20 OD, 20/50 OS Pt surprised that VA OS was decreased. Did not no4ce un4l exam today VMT CASE 2 VMT OS with 20/50 acuity Discussion re op4ons Surgery Monitor Pt elects to monitor, as not bothered by vision and would like to avoid surgery RTC 3 mos with repeat OCT. Pt agrees with plan VMT: when to refer Natural progression of disease is rather variable Slow progression possible with near normal acuity Approx 10% will have spontaneous PVD and resolution within 30 days Therefore, close monitoring my be advised for some patients 8

VMT: when to refer In patients with poor vision, or symptomatic, a pars planar vitrectomy (PPV) may be considered Duration, severity should also be considered Jetrea (ocriplasmin) as option? Literature reports up to a 75% success rate and improvement of vision following PPV MACULAR HOLES LMH 78 year old male Had cataract surgery OS 5 years ago and unhappy with results Feels vision OS is worse now than before surgery No preop data available Unclear if ever explained to cataract surgeon or discussed with him reason for vision loss Unclear what tes4ng was/was not done LMH BCVA 20/20 OD, 20/30 OS Mild NSC OD PCIOL OS. Clear and well centered Post pole: Widefield LMH Lamellar Macula Hole OS Also called par4al thickness macular hole Pt ed. Monitor in 3 mos. Repeat OCT Consider re4na referral if worsens 9

CSR CSR 37 year old male Blurred vision OS x 5 days Black spot centrally OS Spot seems warped BCVA 20/80 OD 20/20 OS Med hx: albuterol PRN for asthma CSR Follow up CSR OD Ask about steroids Albuterol? Ask about stress? RTC for FA n/a Pt presents 1 mos later for FA Feels VA has improved OD significantly 20/20!! FA cancelled! Is this CSR? Pt notes acute onset of bent /crooked lines OD. No real change n vision Last exam 4 years ago at COSTCO CSR When to worry/refer If VA worse than 20/70 If pt demographics do not support If does not resolve in 6 mos If gets worse rather than be]er FA/ OCT does not support diagnosis Just doesn t feel right Pt is unable to accept vision/prognosis 10

CRVO VEIN OCCLUSIONS 75 year old male Presents for 3 mos glc check and 24-2 NTG x2010 Latanaprost qhs OU Has not used x 1 mos. IOP 19mm OU ( 14 ish when treated) Reports noted blurred vision OS about 2 weeks ago OD 20/20 OS 20/200 Type 2 DM and HTN A1C 7.4 BP 134/84 Raster Re4na Clinic CRVO OS with gross macular edema Avas4n series OS x4 Repeat OCT 1 mos afer last injec4on BRVO case 69 yo hispanic male Presents for yearly DM exam. No complaints HTN, DM, Obesity A1c 5.4 BP 154/81 BMI 43.61 VA 20/20 OU BRVO case Increasing edema OD on OCT Approaching macula VA remains 20/20 Pt given op4on of following vs. injec4on, Pt elects to follow RTC 4 mos for repeat OCT 11

CRVO/BRVO Refer if macula edema within 1 week Laser vs. injec4on in BRVO Injec4on CRVO Steroids? Systemic workup recommended DM HTN Cholesterol panel Caro4d Doppler Look for NV/NVI/NVA/NVG esp. in CRVO, esp. if ischemic PLAQUENIL Plaquenil 31 yo AA female Sent from Rheumatology clinic pt on plaquenil. Please do re4nal screen including OCT + Lupus 200 mg HCQ BID x 7 years 20/20 OU 12

Case Normal re4na no evidence of plaquenil maculopathy Le]er back to rheumatology clinic Pt ed RTC 1 yr Plaquenil Be aware of new guidelines Rheumatology clinic/pcps aware HD-OCT, FAF recommended 1 st screening within 1 st year, then afer 5 years Risk factors >10 years Concurrent tamoxifen use Concurrent kidney disease Dose above 5 mg/kg of REAL body weight Incidence sill low, probably 1% Glaucoma GLAUCOMA 70 yo AA male Followed as GlC suspect x 4years Posi4ve family history Mom, maternal GM C/D: OD 0.45; OS 0.50 IOPs: 18-23 OD; 19-23 OS Ini4al 24-2 VF: no defects Ini4al 24-2 VF:August 2012 Todays exam No Complaints VA 20/20 OU IOP 22 mm OD, 23 OS 1+ NSC OU 13

24-2 Right Eye Assessment/Plan POAG OD>OS Start generic latanoprost QHS OU Goal 16 mm OU (30% reduc4on) Pt ed re side effects of g]s RTC 6 weeks for IOP check ANTERIOR SEG Normal angle anatomy Angle closure 14

Epithelial Mapping Conclusion NORMAL OCT has been a game changer in my prac4ce Help make be]er referrals Help keep pa4ents longer Helps take be]er care of your pa4ents Once you get one, not sure how you lived without!!! 15